Literature DB >> 8970410

Cardioversion of atrial fibrillation in the elderly. ALKK-Study Group. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausaerzte.

J Carlsson1, U Tebbe, J Rox, D Harmjanz, K Haerten, K L Neuhaus, F Seidel, W Niederer, S Miketić.   

Abstract

The purpose of this investigation was to define cardioversion success rates, frequency of complications of cardioversion, and current treatment practices in elderly patients (aged > or = 65 years) with atrial fibrillation (AF). The results were compared with those in younger patients (aged < 65 years). The investigation was a prospective multicenter observational study with 61 participating cardiology clinics. Consecutive patients in whom cardioversion of AF was planned had to be prospectively registered. Of 1,152 patients registered, 570 (49.5%) were < 65 years old (group 1) and 582 (50.5%) were > or = 65 years (group 2). The overall success rate of cardioversion on an intention-to-treat basis was 76.1% in group 1 and 72.7% in group 2 (p = 0.18). In multivariate analysis, left atrial size and New York Heart Association functional class before cardioversion were identified as predictors of success (p < 0.001, respectively; p = 0.025). These clinical factors were not equally distributed between the age groups: Left atrial size was larger in the elderly than in younger patients (44.0 +/- 6.4 mm vs 42.8 +/- 6.4 mm; p = 0.006) and a New York Heart Association functional class > or = II was more prevalent in group 2 than in group 1 (48.6% vs 29.6%; p < 0.001). The overall complication rates were not significantly different between the 2 groups (4.2% in group 1 vs 5.3% in group 2; p = 0.37). The frequency of patients who were adequately anticoagulated for cardioversion was 56.9% in age group 1 and 39.6% in age group 2 (p < 0.001). In chronic AF the same trend for age-dependent underuse of anticoagulation was observed. Age itself was not a predictor of cardioversion success and did not predispose to higher complication rates. Therefore, cardioversion should be considered in older patients with the same criteria and emphasis as in younger patients. Anticoagulation and antithrombotic medication is underused for cardioversion and in treating chronic AF, especially in elderly patients.

Entities:  

Mesh:

Year:  1996        PMID: 8970410     DOI: 10.1016/s0002-9149(96)00647-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  [Patients suffering from atrial fibrillation in Germany. Characteristics, resource consumption and costs].

Authors:  T Reinhold; S Rosenfeld; F Müller-Riemenschneider; S N Willich; T Meinertz; P Kirchhof; B Brüggenjürgen
Journal:  Herz       Date:  2012-08       Impact factor: 1.443

2.  [Not Available].

Authors:  J Carlsson; S Haun; S Miketic; U Tebbe
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1998-02

3.  Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.

Authors:  Anna Nergärdh; Rolf Nordlander; Mats Frick
Journal:  Clin Cardiol       Date:  2006-02       Impact factor: 2.882

4.  Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.

Authors:  A E Tuinenburg; I C Van Gelder; M P Van Den Berg; J Brügemann; P J De Kam; H J Crijns
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

5.  Usefulness of transoesophageal echocardiography before cardioversion in patients with atrial fibrillation and different anticoagulant regimens.

Authors:  A Maltagliati; C A Galli; G Tamborini; A Calligaris; E Doria; R Salehi; M Pepi
Journal:  Heart       Date:  2005-11-11       Impact factor: 5.994

Review 6.  Atrial fibrillation in the elderly: facts and management.

Authors:  Guy Chatap; Karine Giraud; Jean-Pierre Vincent
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Factors influencing immediate and long-term outcome of electrical cardioversion of persistent atrial fibrillation and flutter.

Authors:  S Tabery; L Bouwels; G J H Uijen; A Uppelschoten; F W A Verheugt
Journal:  Neth Heart J       Date:  2001-04       Impact factor: 2.380

Review 8.  Current treatment recommendations in antiarrhythmic therapy.

Authors:  I C Van Gelder; J Brügemann; H J Crijns
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

9.  Gender differences in patients with atrial fibrillation.

Authors:  Ralph F Bosch; David Pittrow; Anne Beltzer; Irmtraut Kruck; Wilhelm Kirch; Annette Kohlhaussen; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-08-27

10.  Short-term and long-term success of electrical cardioversion in atrial fibrillation in managed care system.

Authors:  Suman S Kuppahally; Elyse Foster; Stanford Shoor; Anthony E Steimle
Journal:  Int Arch Med       Date:  2009-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.